Log In
Print
BCIQ
Print
Print this Print this
 

imilecleucel-T (Tcelna) (formerly Tovaxin)

Also known as: T-cell vaccine

  Manage Alerts
Collapse Summary General Information
Company Opexa Therapeutics Inc.
DescriptionPatient-specific myelin reactive T cells (MRTCs) primed and expanded ex vivo with myelin-associated peptides
Molecular Target T cell receptor (TCR)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase II
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS); Treat secondary progressive multiple sclerosis (SPMS)
Regulatory Designation

U.S. - Fast Track (Treat secondary progressive multiple sclerosis (SPMS))

Partner

Merck KGaA


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today